We Work for Health | Washington

04/03/2026

"Despite 340B providing discounted drugs to eligible hospitals to ensure access to care for vulnerable patient populations, 340B hospitals in most states are experiencing significantly more growth in assets than spending on uncompensated care, on a per bed basis."

04/01/2026

Tune in to understand how the U.S. could lose the biopharma leadership edge due to policy: https://www.youtube.com/watch?v=Hl93fvSdK_Q

03/30/2026

"Changing insurance has proven to be a full-time job on top of what already is a full-time job living as a disabled patient."

Insurance abuse upended patient Sarah's care routine. Read more about the impacts:

Opinion Piece: Insurance Abuse Post author:Patient Worthy Contributor Post published:March 26, 2026 Post category:Ehlers-Danlos Syndrome Editor’s Note: The views, thoughts, and opinions expressed in this article belong solely to the author and do not necessarily reflect the position of Patient wor...

03/27/2026

"America’s biopharmaceutical leadership and the health and economic benefits it brings are at risk. U.S. policymakers are considering or are already pursuing steps that would erode the very foundations of the country’s innovation ecosystem."

Including MFN:

Europe once led the world in biopharmaceutical innovation, but it lost ground after adopting policies that weakened incentives for R&D and innovation. America must learn from Europe’s experience to preserve its own biopharma leadership and the related economic benefits and access to the most innov...

03/25/2026

"Despite providing discounted drugs to eligible hospitals to ensure access to care for vulnerable patient populations, 340B hospitals in most states are experiencing significantly more growth in assets than spending on uncompensated care."

https://healcollaborative.org/magnolia-market-access-analysis/

03/23/2026

"If Japan paid the same price for drugs as Americans do, biotech companies would earn an additional $36 billion in revenue."

is a bad business deal for the U.S.: https://www.realclearhealth.com/articles/2026/03/19/trump_can_stop_japans_free-riding_on_american_innovation_1171396.html

03/20/2026

"These policies restrict the availability of breakthrough treatments for Japanese patients and place a greater share of the cost of global medical innovation on American patients."

puts the U.S. at an international disadvantage:

President Trump will soon welcome Prime Minister Sanae Takaichi to Washington for a high-profile U.S.-Japan summit. Given what’s at stake for patients and

03/18/2026

"Voluminous evidence confirms that implementing MFN price controls will reduce investment in research, development, and discovery of beneficial new drugs."

Read about the economic impacts of on American industries: https://www.washingtonexaminer.com/op-eds/4488743/trump-most-favored-nation-threatens-us-competitiveness-china/

03/18/2026

"That free-riding is unfair. But it’s also a very tangible threat to our economy and our health. If American companies are losing tens of billions in revenue, they cannot hire as many workers or develop as many life-saving treatments."

https://www.washingtonexaminer.com/opinion/4486552/drug-pricing-top-of-agenda-trump-takaichi-meeting/

03/13/2026

"When insurers control both the PBM that determines which drugs are “preferred” and the pharmacies where prescriptions must be filled, corporate policy can override the doctor‑patient relationship."

operate as a dangerous middleman when unchecked: https://www.wyomingnews.com/opinion/guest_column/leslie-health-care-decisions-should-be-made-close-to-home-not-in-corporate-boardrooms/article_75697df3-df8a-429e-a56b-d4efd0fcd558.html

03/11/2026

"Today's drug pricing proposals overlook this fragile balance. If Medicare price controls or MFN models drive down reimbursement rates while acquisition costs stay the same — or climb higher due to tariffs — independent practices will be left underwater."

https://www.nola.com/opinions/guest_columns/guest-column-drug-pricing-reforms-cannot-neglect-independent-practitioners/article_03ea9366-87d9-40f9-a2ca-127fabba76c1.html

03/10/2026

"It would be a tragic mistake for the U.S. to move forward with a well-intentioned but flawed plan to tie drug prices to European health systems where QALY-based cost-effectiveness frameworks influence pricing and reimbursement decisions."

https://www.thewellnews.com/opinions/dont-adopt-europes-discriminatory-drug-pricing-against-individuals-with-down-syndrome/